Roche’s breast cancer pill giredestrant, given together with everolimus, reduced the risk of tumor progression by 62% in patients whose cancer carries an ESR1 mutation and by 44% across all patients in a closely watched Phase 3 study.
The company, the disease and the drug
Roche is a Swiss healthcare company that develops and sells treatments for multiple diseases, and it is a powerhouse in biotech and cancer research.
The disease in question is ER-positive, HER2-negative breast cancer, a common type. The cancer cells have estrogen receptors (ER) and grow in response to the hormone estrogen. They lack the HER2 protein, which means they are driven by hormones instead of HER2. About 70% of breast cancer cases are ER-positive. ESR1 is a mutation within a mutation, a gene change that these cancer cells develop after hormone therapy.
The treatment under review pairs two drugs. Giredestrant blocks and breaks down the ER in cancer cells, which makes the cell go dormant or even die. Everolimus blocks the cell’s internal growth pathway, the one that helps it survive even without its ER.
What the trial showed
The standard first-line treatment for ER-positive, HER2-negative breast cancer is endocrine therapy plus a CDK4/6 inhibitor. The Phase 3 evERA trial, in the post-CDK4/6 inhibitor setting, compared the new combination of giredestrant and everolimus against older endocrine therapy plus everolimus.
These are Roche’s results only. According to the company’s data, the combination lowered the risk of progression or death by about 62% in the ESR1-mutated subgroup and by about 44% in the overall population, which includes both ESR1-mutated and non-mutated patients. In the ESR1-non-mutated subgroup the benefit was small, a 15% risk reduction that was not statistically significant.
Outlook
For breast cancer research and treatment, this trial marks a major step forward. Progress in the field continues to accelerate, and in the future we may even see giredestrant replaced by an even more effective therapy.
Roche as a company will greatly benefit. If it continues to develop more treatments for major illnesses, exponential growth will definitely be on the horizon, and its valuation will go through the roof.
As a treatment, slowing cancer progression by 62% is an amazing feat, one that giredestrant’s rivals Inluriyo (38%) and Orserdu (45%) cannot compete with. Right now it caters mainly to people in the ESR1-mutated subgroup of breast cancer, but it may be refined to serve the overall population far more in the future. The only concern for now is how well people tolerate the drug.